高级搜索
蔡卫, 陈宏璘, 张建永, 杨远维, 王洁, 彭康. 白花丹醌通过E-cadherin增强替莫唑胺对人脑胶质瘤U251细胞迁移和侵袭的抑制作用[J]. 肿瘤防治研究, 2021, 48(6): 576-580. DOI: 10.3971/j.issn.1000-8578.2021.21.0027
引用本文: 蔡卫, 陈宏璘, 张建永, 杨远维, 王洁, 彭康. 白花丹醌通过E-cadherin增强替莫唑胺对人脑胶质瘤U251细胞迁移和侵袭的抑制作用[J]. 肿瘤防治研究, 2021, 48(6): 576-580. DOI: 10.3971/j.issn.1000-8578.2021.21.0027
CAI Wei, CHEN Honglin, ZHANG Jianyong, YANG Yuanwei, WANG Jie, PENG Kang. Plumbagin Enhanced Inhibitory Effect of Temozolomide on Migration and Invasion of Human Glioma U251 Cells Through E-cadherin[J]. Cancer Research on Prevention and Treatment, 2021, 48(6): 576-580. DOI: 10.3971/j.issn.1000-8578.2021.21.0027
Citation: CAI Wei, CHEN Honglin, ZHANG Jianyong, YANG Yuanwei, WANG Jie, PENG Kang. Plumbagin Enhanced Inhibitory Effect of Temozolomide on Migration and Invasion of Human Glioma U251 Cells Through E-cadherin[J]. Cancer Research on Prevention and Treatment, 2021, 48(6): 576-580. DOI: 10.3971/j.issn.1000-8578.2021.21.0027

白花丹醌通过E-cadherin增强替莫唑胺对人脑胶质瘤U251细胞迁移和侵袭的抑制作用

Plumbagin Enhanced Inhibitory Effect of Temozolomide on Migration and Invasion of Human Glioma U251 Cells Through E-cadherin

  • 摘要:
    目的 探讨白花丹醌增强替莫唑胺对人脑胶质瘤U251细胞迁移和侵袭的抑制作用及其机制。
    方法 CCK-8法检测白花丹醌、替莫唑胺、白花丹醌+替莫唑胺组对U251细胞增殖的影响;细胞划痕实验检测对照组(DMSO)、白花丹醌、替莫唑胺和白花丹醌+替莫唑胺组U251细胞48 h的迁移能力;Transwell实验检测白花丹醌增强替莫唑胺对U251细胞侵袭的影响;蛋白质印迹法检测白花丹醌、替莫唑胺和白花丹醌+替莫唑胺组细胞中E-cadherin的相对表达量。
    结果 CCK-8结果显示白花丹醌(1.25 μmol/L)联合替莫唑胺(200 μmol/L)处理48 h后,U251细胞增殖抑制率为75.69%,明显高于单独应用白花丹醌(P=0.012)或替莫唑胺组(P=0.034)。细胞划痕实验显示白花丹醌联合替莫唑胺可以明显增强替莫唑胺抑制胶质瘤细胞迁移的能力(P=0.023)。Transwell实验
    结果 显示联合用药后U251细胞的侵袭能力明显降低(P < 0.05)。联合用药组E-cadherin蛋白表达含量明显高于单独用药组(P < 0.05)。
    结论 白花丹醌联合替莫唑胺可以抑制胶质瘤细胞的迁移和侵袭、增强胶质瘤细胞对替莫唑胺的敏感度,且是通过E-cadherin蛋白表达实现的。

     

    Abstract:
    Objective To investigate the inhibitory effect and mechanism of temozolomide on migration and invasion of U251 human glioma cells enhanced by plumbagin.
    Methods CCK-8 method was used to study the effects of plumbagin, temozolomide and plumbagin+temozolomide on the proliferation of glioma U251 cells. Cell scratch test was used to detect the migration of U251 cells in the control (DMSO), plumbagin, temozolomide and plumbagin+temozolomide groups for 48h. Transwell assay was used to detect the effect of the combination therapy on the invasion of U251 cells. Western blot was used to detect the relative expression levels of E-cadherin in three groups.
    Results CCK-8 showed that the proliferation inhibition rate of U251 cells treated with plumbagin (1.25 μmol/L) combined with temozolomide (200 μmol/L) for 48h was 75.69%, significantly higher than that treated with plumbagin alone (P=0.012) or temozolomide alone (P=0.034). Cell scratch assay showed that the combination of plumbagin and temozolomide could significantly enhance the inhibition effect of temozolomide on the migration of U251 cells (P=0.023). Transwell assay showed that the invasion ability of U251 cells was significantly decreased after the combination therapy (P < 0.05). The protein expression of E-cadherin in the combination group was significantly higher than those in plumbagin or temozolomide groups (P < 0.05).
    Conclusion Plumbagin combined with temozolomide can inhibit the migration and invasion of glioma cells and enhance the sensitivity of glioma cells to temozolomide. And the effect is achieved by the protein expression of E-cadherin.

     

/

返回文章
返回